Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | GAA | P10253 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.63 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.63 |
| ▸ | GFER | P55789 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | CHKA | P35790 | 2/20 | 0.56 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21382095 | 0.98 | MAPT (0.61) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL111714 | 0.85 | GAA (0.62) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL8353735 | 0.83 | CHKA (0.57) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL3840667 | 0.82 | L3MBTL1 (0.55) | MAPTGAAALDH1A1KDM4EKMT2A | |
| SCHEMBL20340801 | 0.82 | CHKA (0.53) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL15392533 | 0.81 | CHKA (0.65) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL3596202 | 0.81 | CHKA (0.56) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL18774112 | 0.81 | CHKA (0.56) | MAPTGAAALDH1A1KDM4EPTK2B | |
| SCHEMBL5987861 | 0.81 | TAAR1 (0.67) | MAPTALDH1A1KDM4EGFERKMT2A | |
| Hydrochloric Acid SCHEMBL25322183 | 0.81 | L3MBTL1 (0.59) | MAPTGAAALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| CN-111051309-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-26 | — | — | CN | disclosed |
| CN-110467629-B | Benzoquinone derivative, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3814356-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| CN-111051309-A | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | MAPT 2364/4885GAA 3530/4885ALDH1A1 2323/4885 |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | MAPT 3868/4885GAA 4192/4885ALDH1A1 571/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | MAPT 3868/4885GAA 4192/4885ALDH1A1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.